Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Tumor Growth”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT01737008
What this trial is testing

Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck

Who this might be right for
Squamous Cell Carcinoma of the Head and Neck
University Health Network, Toronto 12
Not applicableWithdrawnNCT03519958
What this trial is testing

Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca
Testing effectiveness (Phase 2)Study completedNCT03797326
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

Who this might be right for
Advanced Solid TumorsTriple Negative Breast CancerOvarian Cancer+5 more
Merck Sharp & Dohme LLC 611
Testing effectiveness (Phase 2)Ended earlyNCT00225758
What this trial is testing

Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy

Who this might be right for
Metastatic Breast Cancer
Gary Schwartz 27
Not applicableLooking for participantsNCT05209776
What this trial is testing

Local Inflammation in Arrhythmogenic Right Ventricular Cardiomyopathy

Who this might be right for
Arrhythmogenic Right Ventricular Dysplasia
University Hospital, Toulouse 80
Testing effectiveness (Phase 2)Active Not RecruitingNCT06120140
What this trial is testing

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 305
Large-scale testing (Phase 3)Active Not RecruitingNCT05607550
What this trial is testing

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Who this might be right for
Metastatic Non-Small Cell Lung CancerAdvanced Non-Small Cell Lung CancerEGFR Exon 20 Mutations
ArriVent BioPharma, Inc. 398
Large-scale testing (Phase 3)Study completedNCT01908426
What this trial is testing

Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib

Who this might be right for
Hepatocellular Carcinoma
Exelixis 707
Early research (Phase 1)Study completedNCT00551850
What this trial is testing

A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients

Who this might be right for
Advanced CancerRefractory Cancer
AVEO Pharmaceuticals, Inc. 37
Early research (Phase 1)Study completedNCT02228369
What this trial is testing

Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer

Who this might be right for
EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
AstraZeneca 108
Early research (Phase 1)Ended earlyNCT01004822
What this trial is testing

A Safety, Tolerability, And Pharmacokinetic Trial With CVX-241 In Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Pfizer 31
Post-approval studies (Phase 4)Study completedNCT03853551
What this trial is testing

Osimertinib Study in Indian Patients

Who this might be right for
Non Small Cell Lung Cancer (NSCLC)
AstraZeneca 60
Early research (Phase 1)Study completedNCT03834662
What this trial is testing

A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies

Who this might be right for
Malignant Solid Tumor
Bristol-Myers Squibb 19
Early research (Phase 1)Active Not RecruitingNCT05222802
What this trial is testing

Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)

Who this might be right for
Glioblastoma Multiforme
Katmai Pharmaceuticals Inc. 52
Large-scale testing (Phase 3)Study completedNCT01774721
What this trial is testing

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Who this might be right for
Non-small Cell Lung Cancer With EGFR-Activating Mutations
Pfizer 452
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05982275
What this trial is testing

Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant

Who this might be right for
Multiple MyelomaAllogeneic Stem Cell Transplantation
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla 25
Not applicableUnknownNCT01850628
What this trial is testing

NSABP Biospecimen Discovery Project

Who this might be right for
Breast Cancer
NSABP Foundation Inc 50
Not applicableUnknownNCT03990675
What this trial is testing

Evaluation and Comparison of the Growth Rate of Pancreatic Cancer Patient-derived Organoids

Who this might be right for
Pancreas Cancer
Technical University of Munich 50
Large-scale testing (Phase 3)Study completedNCT01935492
What this trial is testing

8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer

Who this might be right for
Human Epidermal Growth Factor 2 Negative Carcinoma of BreastMetastatic Breast Cancer
Borstkanker Onderzoek Groep 420
Early research (Phase 1)Study completedNCT04187898
What this trial is testing

Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer

Who this might be right for
NeutropeniaBreast Cancer
Spectrum Pharmaceuticals, Inc 59
Next Page